IMI Call for Proposals with Focus on Alzheimer's Disease, Diabetes, Patient Involvement

The Innovative Medicines Initiative (IMI)The Innovative Medicines Initiative (IMI) has launched its 5th Call for proposals under the IMI 2 programme. IMI 2 - Call 5 has a total budget of €95 million and features 6 topics. Of these, four focus on different aspects of Alzheimer's disease, one focuses on diabetic kidney disease, and one addresses patient input on assessments of the benefits and risks of medicines.

Four topics focus on Alzheimer's disease, an area where there is an urgent need for new treatments.

Inflammation and Alzheimer's disease: This topic aims to identify new drug targets for Alzheimer's disease focusing on two proteins (called TREM2 and CD33) that are linked to inflammation and are thought to affect people's risk of developing Alzheimer's disease.

Amyloid imaging biomarkers: Many people with Alzheimer's disease have clumps of protein called amyloid plaques in their brains. This topic will seek to review the usefulness of knowing a patient's amyloid brain status for diagnosis and treatment, and determine the value of amyloid imaging in drug development.

Alzheimer's disease and patient engagement: Dementia researchers are increasingly focusing their efforts on finding ways to prevent the onset of Alzheimer's symptoms in the first place. The goal of this topic is to identify the most effective ways of identifying and engaging with people who are in the very earliest stages of the disease. This will add to our understanding of the early stages of the disease, help patients access support from early on in their disease, and facilitate recruitment for clinical trials.

Apolipoprotein E (ApoE) biology: People who have the ApoE4 gene are at greater risk of developing Alzheimer's disease. This topic will explore precisely how ApoE4 influences the development of Alzheimer's disease and pave the way for new treatment strategies for Alzheimer's and better identification of individuals at greatest risk for developing the disease.

The topic on diabetes is designed to address the need for biological markers of diabetic kidney disease (DKD). DKD is a common complication of diabetes; the biological markers will add to our understanding of DKD and will advance the development and evaluation of new treatments for DKD.

In line with IMI's goal of boosting patient involvement in research, the Call also features a topic that will explore when and how best to gain patients' input on the benefits and risks of medicines, at all stages of the drug development life cycle, to inform decision-making processes.

Irene Norstedt, IMI Acting Executive Director commented: "With the launch of this Call for proposals, IMI once again affirms its commitment to tackling some of the biggest public health challenges facing Europe today - Alzheimer's disease and diabetes. At the same time, the fact that we have two topics dedicated to patient engagement underlines IMI's role as a platform for multi-stakeholder collaboration."

The deadline for submitting short proposals is 13 October 2015.

Half of the Call's budget (€47.5 million) comes from the European Commission through the Horizon 2020 programme for research and innovation. The other half will be contributed by EFPIA companies involved in the projects as well as other Associated Partners. These groups do not receive any funding from IMI, but contribute 'in kind' with their researchers' time, access to resources and equipment, etc.

For further information on the new Call for proposals, including all topic texts and details of how to apply, can be found on the IMI website:
http://www.imi.europa.eu/content/stage-1-16

About the Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.

IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI 2 programme, IMI has a budget of €3.3 billion for the period 2014-2024. Half of this comes from the EU's research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources.

Most Popular Now

Artificial Intelligence Solution Improve…

Clinical trials are a critical tool for getting new treatments to people who need them, but research shows that difficulty finding the right volunteer subjects can undermine the effectiveness of...

South West London Pathology Picks CliniS…

One of the first pathology networks in the country, set up to serve more than two million people in south west London, has signed a contract with CliniSys for a...

Call for Tenders: Studies on eHealth, In…

The European Commission is launching a tender for two studies to survey and analyse progress on the digital transformation of the health and care in the EU, in particular with...

AI-based AI-Rad Companion Chest CT Softw…

AI-Rad Companion Chest CT(1), an intelligent software assistant for radiology, was recently awarded the CE mark, which means Siemens Healthineers can start marketing this artificial intelligence (AI)-based software as a...

Spot On for Healthcare Technology Startu…

10 - 12 October 2019, Berlin, Germany. XPOMET Medicinale brings together care providers, patients, and in general stakeholders from all health-related fields and geographic regions. The Festival of Future Medicine and...

Isansys Named as Finalist for OBN's Most…

Isansys Lifecare is proud to announce it has been shortlisted in the Most Transformative Digital Healthcare Company category at the OBN Annual Awards 2019. The award recognises the significant uptake...

7th MEDICA MEDICINE + SPORTS CONFERENCE

18 - 21 November 2019, Düsseldorf, Germany. What lengths do top athletes go to in order to reach peak performances and which findings in the field of professional sports are relevant...

How can We Successfully Converge the Hea…

Opinion Article by Erik Janssen, VP, Innovative Solutions, Neurology, UCB Pharma. The fourth industrial revolution is upon us and fundamentally changing the way we live, work and interact across all industries...

Carestream Health Completes Sale of Heal…

Carestream Healthhas completed the sale of the company's healthcare information solutions business to Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, in 26 of the 38...

Allscripts Listed on Lot One of Health S…

Allscripts has been included on a new list of accredited suppliers of electronic patient records that has been published by NHS England and NHSX. The company is one of just...